huTGFBI-R124H Mouse
Product Name
huTGFBI-R124H Mouse
Product ID
C002005
Strain Name
C57BL/6JCya-Tgfbitm2(hTGFBI*R124H)/Cya
Backgroud
C57BL/6JCya
Status
When using this mouse strain in a publication, please cite “huTGFBI-R124H Mouse (Catalog C002005) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
TGFBI
Gene Alias
CSD, CDB1, CDG2, CSD1, CSD2, CSD3, EBMD, LCD1, BIGH3, CDGG1
NCBI ID
Chromosome
Chr 5 (Human)
MGI ID
Datasheet
Strain Description
Corneal dystrophy (CD) refers to a group of primary hereditary progressive corneal diseases. The typical clinical presentation involves gradual loss of corneal transparency in both eyes, often leading to recurrent corneal erosions and visual impairment. The TGFBI gene (also known as BIGH3) encodes an extracellular matrix protein called keratoepithelin (KE protein), which plays a role in cell growth, differentiation, wound healing, cell adhesion, migration, apoptosis, proliferation, and tumorigenesis [1]. Mutations in the TGFBI gene are associated with various types of corneal dystrophy. Abnormal accumulation of mutated TGFBI deposits in the corneal epithelium and stroma progressively affects corneal transparency, leading to visual impairment.
The R124H mutation represents one of the most clinically significant genetic alterations within the TGFBI gene, specifically resulting from a missense mutation. This particular mutation is the definitive genetic cause of Granular Corneal Dystrophy type 2 (GCD2), also historically referred to as Avellino corneal dystrophy [2]. Unlike other variants that may produce a single type of protein deposit, the R124H mutation is characterized by a "mixed" pathology, leading to the simultaneous accumulation of both crumb-like granular deposits and proteinaceous lattice-like amyloid fibrils within the corneal stroma. Furthermore, the R124H mutation is notoriously sensitive to external trauma, meaning that refractive surgeries like LASIK or PRK can trigger a massive, accelerated inflammatory response and a surge in protein deposition, which often necessitates corneal transplantation to restore sight [3]. Thus, developing gene therapy is crucial for this patient population.
huTGFBI-R124H mice are generated by introducing the R124H mutation into the human TGFBI gene and subsequently knocking out exon 13 in huTGFBI mice (Catalog Number: C001546) using gene editing technology. This strain can be used for studying the pathological mechanisms and treatments of Granular Corneal Dystrophy type 2 (GCD2), as well as for the development of TGFBI-targeted drugs.
Reference
Wang L, Zhao C, Zheng T, Zhang Y, Liu H, Wang X, Tang X, Zhao B, Liu P. Torin 1 alleviates impairment of TFEB-mediated lysosomal biogenesis and autophagy in TGFBI (p.G623_H626del)-linked Thiel-Behnke corneal dystrophy. Autophagy. 2022 Apr;18(4):765-782.
Yamazoe K, Yoshida S, Yasuda M, Hatou S, Inagaki E, Ogawa Y, Tsubota K, Shimmura S. Development of a Transgenic Mouse with R124H Human TGFBI Mutation Associated with Granular Corneal Dystrophy Type 2. PLoS One. 2015 Jul 21;10(7):e0133397.
Park JE, Yun SA, Roh EY, Yoon JH, Shin S, Ki CS. Prevalence of granular corneal dystrophy type 2-related TGFBI p.R124H variant in a South Korean population. Mol Vis. 2021 May 8;27:283-287.
Strain Strategy
Figure 1. Gene editing strategy of huTGFBI (Catalog Number: C001546) mice. The sequences from Eoxn 1 to TAG stop codon of mouse Tgfbi were replaced with the sequences from Eoxn 1 to TAG stop codon of human TGFBI. The murine signal peptide was kept.
Figure 2. Diagram of the gene editing strategy for the generation of huTGFBI-R124H mice. The R124H mutation was introduced into exon 4 of the humanized TGFBI gene in huTGFBI mice. Exon 13 was selected as the KO region.
Application Area
Research on the pathological mechanisms and treatments of Granular Corneal Dystrophy type 2 (GCD2);
Development, screening, and preclinical evaluation of TGFBI-targeted drugs.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.